NewsEvents

Your Yourlocation: Home > Clinical observation of tiotropium bromide(136310-93-5) combined with budesonide in the treatment of uncontrolled asthma in adults

Objective: To study the efficacy of tiotropium bromide(136310-93-5) combined with budesonide in the treatment of uncontrolled asthma in adults.

Methods: 96 uncontrolled asthma were randomly divided into three groups: group A was treated with tiotropium bromide(136310-93-5) and budesonide, group B was given double dose of budesonide, and C was treated with formoterol combined with budesonide.  The frequency of expiratory volume, the rate of lung function, the scores of ACT, the number of acute attacks and the adverse reactions were observed before and after treatment.

Results: Compared with group B, the improvement of expiratory volume(PEF) and forced expiratory volume(FEV1) in morning and evening were statistically significant (P <0.05 ). There was no significant difference in the morningtime, evening expiratory flow(PEF) and forced expiratory volume(FEV1) between the first and second groups (P> 0.05).

Conclusion: Combined with tiotropium bromide(136310-93-5) treatment was superior to ICS dose doubling when patients were treated with budesonide at 800 μg /d for poor treatment. Consistent with previous studies, formoterol was effective and tiotropium did not inferior to formoterol.

Bronchial asthma is a chronic respiratory disease that manifests itself as reversible airway obstruction leading to allergic inflammation and excessive contraction of bronchial smooth muscle. At present, anti-inflammatory drugs [mainly inhaled glucocorticoid (ICS)] and bronchodilators [mainly inhaled long-acting beta2 agonists (LABA)] have been widely used for asthma, based on the understanding of the pathogenesis of asthma treatment.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved